Related Experiment Video
Updated: Jun 15, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Dopamine receptor 3 (DRD3) polymorphism and risk for migraine
E García-Martín1, C Martínez2, M Serrador3
1Biochemistry & Molecular Biology, School of Biological Sciences, University of Extremadura, Badajoz, Spain.
European Journal of Neurology
|March 19, 2010
Summary
The dopamine D3 receptor (DRD3) gene polymorphism rs6280 is not associated with migraine risk in Caucasian Spanish individuals. However, the DRD3Gly9Gly9 genotype was more frequent in migraine with aura patients compared to those without aura.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Dopamine plays a role in migraine pathogenesis.
- The DRD3 gene (rs6280) polymorphism on chromosome 3q13 is a potential factor in migraine susceptibility.
Purpose of the Study:
- To investigate the association between the DRD3 gene polymorphism (rs6280) and migraine risk.
- To explore the link between this polymorphism and alcohol-triggered migraine attacks.
Main Methods:
- Genotyping of DRD3 (rs6280) in 197 migraine patients and 282 controls using PCR and RFLP.
- Analysis of genotype and allele frequencies in relation to migraine status, aura, and alcohol triggers.
Main Results:
- No significant difference in DRD3 genotype or allele frequencies between migraine patients and controls.
- DRD3 genotype and allele frequencies were not linked to migraine onset age, gender, family history, or alcohol triggers.
- The DRD3Gly9Gly9 genotype was more prevalent in migraine with aura patients versus migraine without aura patients, but not compared to controls.
Conclusions:
- DRD3 genotype and allelic variants are not associated with overall migraine risk in the studied Caucasian Spanish population.
- The DRD3Gly9Gly9 genotype may be associated with migraine with aura, warranting further investigation.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...